InflaRx to Showcase Vilobelimabs Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company…
New Biovanta Study Shows Best Efficacy in Treating Common Cold
Newcomer to OTC cold market offers clinically proven alternative with anti-inflammatory and…
